Hydrophilic Stent Coating Inhibits Platelet Adhesion on Stent Surfaces: Initial Results In Vitro

Tim Lenz-Habijan1 · P. Bhogal2 · Marcus Peters3 · Albrecht Bufe3 · Rosa Martinez Moreno4 · Catrin Bannewitz1 · Hermann Monstadt1 · Hans Henkes2,5

Received: 5 March 2018 / Accepted: 20 May 2018 / Published online: 23 July 2018 © The Author(s) 2018

Abstract

Background Endovascular stents and flow diverter stents (FDS) have revolutionized the treatment of intradural aneurysms; however, the need for dual anti-platelet treatment (DAPT) limits their use and can cause additional issues. Therefore, there is a need to develop stent coatings that negate the need for DAPT.

Methods Two different hydrophilic polymer coatings (HPC-I and HPC-II) were used to coat small nickel titanium plates to initially test the hydrophilic properties of these coatings when applied to nickel titanium. The plates were subsequently incubated with non-medicated whole blood from healthy volunteers for 10 min and stained with a CD61 immunofluorescent antibody that allows detection of adherent platelets. The coatings were applied to FDS wires and were again incubated with non-medicated whole blood from the same volunteers. Scanning electron microscopy was used to detect adherent platelets on the wire surface.

Results The HPC-II coating (1.12 ± 0.4%) showed a significantly lower CD61+ cell count (p < 0.001) compared to both uncoated NiTi plates (48.61 ± 7.3%) and those with the HPC-I coating (mean 40.19 ± 8.9%). Minimal adherent platelets were seen on the FDS nickel titanium wires coated with the HPC-II compared to uncoated FDS under electron microscopy.

Conclusion There is a significant decrease in the number of adherent CD61+ platelets on nickel titanium surfaces coated with the HPC-II coating compared to uncoated surfaces. The coating can be successfully applied to the wires of flow diverters. The results of this study are promising with regard to the development of new anti-thrombogenic endovascular devices.

Keywords Flow diverter stent · Anti-thrombogenic coating · Anti-platelet

Introduction

During the last decade, we have witnessed the emergence of flow diverting stents (FDS) that are designed to treat intracranial aneurysms without the adjunctive implantation of coils. Although the exact mechanism by which flow diverters work remains elusive, it is thought the redirection of flow away from the aneurysmal sac and altered intraneurysmal flow with gradual thrombosis all play a role in the early stabilization of aneurysms with subsequent neo-endothelialization eventually remodelling the vessel wall and excluding aneurysm from the circulation [1]. These devices were originally evaluated in otherwise untreatable aneurysms or after failure of other endovascular treatments [2, 3], but numerous single-centre studies and meta-analyses have also been published demonstrating the efficacy and safety profile of these devices [4–13]. To date, six devices are available (Pipeline, Medtronic; FRED,
MicroVention; Silk, Balt Extrusion; Surpass/Streamline, Stryker; Derivo, Acandis; p64 Flow Modulation Device and p48 Flow Modulation Device, both phenox) with newer devices in development.

Although flow diverters have revolutionized the treatment of aneurysms, one major issue remains unsolved. Due to the thrombogenic surface, platelet function-inhibiting drugs are needed to prevent in-stent thrombosis. However, these drugs are not without clinical consequences. Since the beginning of stenting as an endovascular therapeutic technique, early thrombosis in stented arterial segments has been a major concern [14]. The overall rate in the early clinical experience was as high as 24%. They were initially treated by aggressive anti-aggregation regimens, which reduced the incidence of thrombotic events, but this was associated with an increased rate of haemorrhagic complications [15]. With time, anti-platelet therapy alone demonstrated superior clinical results compared to other anti-thrombotic treatments in several studies [15, 16]. Typically, the dual anti-platelet regime (DAPT) consists of aspirin and clopidogrel for at least 3 months with continuation of aspirin for life thereafter. Naturally, there are issues regarding an increased bleeding risk and the ‘holy grail’ of endovascular implants is haemo-compatibility that does not require anti-platelet agents. Recently, the Pipeline Shield (Medtronic) has entered the market. This device, the first FDS with a thrombo-resistant coating, has a 3 nm thick covalently bound phosphorylcholine surface modification. Phosphorylcholine is a major component of the outer membrane of erythrocytes and has demonstrated efficacy in resisting platelet adhesion as well as intimal hyperplasia [17–19]. However, at the moment there are limited clinical data available on the use of this technology.

It is imperative to identify other potential surface coatings or modifications that may reduce thrombogenicity of stents. The purpose of this study was to develop and evaluate two new anti-thrombogenic stent coatings. The best coating was then tested on two FDS—the p64 and the p48 (phenox GmBH, Bochum, Germany).

Materials and Methods

Specimens and Coatings

Small nickel titanium plates (9 × 9 × 0.5 mm) and flow diverters served as substrate for the coating. The nickel titanium plates were laser-cut out of 0.5 mm thin nickel titanium sheets. In order to remove contaminations from the laser cutting process and to ensure a homogeneous TiO₂, all plates were electrolytically polished and passivated. Two different hydrophilic polymer coatings (HPC-I and HPC-II) were applied on the specimens. HPC-I is a well-known polyethylene glycol (PEG)-based coating. HPC-II is a newly developed glycan-based multilayer polymer coating.

Hydrophilic Testing

Small droplets of water are applied on the uncoated nickel titanium plates and uncoated FDS using a micropipette (Eppendorf® Research® plus; 2–20 µL) with 20 µL applied to the nickel titanium plates and 2 µL applied to the braided flow diverter stents. Changes in the hydrophilic properties of the coated samples were used to monitor coating efficiency.

Blood Donors

Blood was voluntarily collected from eight healthy donors under the approval of the ethic commission of the Faculty of Medicine of the Ruhr-Universität Bochum, Germany (registration number: 16-5991). Exclusion criteria for participation in the study were an abnormal blood count measured via haematology analyser (KX-21 N, Sysmex, Norderstedt, Germany) and the intake of drugs that act on blood clotting. The number of platelets in the blood was recorded for each donor (not shown).

Informed consent was obtained from all individual participants included in the study.

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Blood Contact In Vitro

All steps were performed under sterile conditions. Heparinized venous blood was collected using the “S-Monovette Blood collection system” (Sarstedt, Germany) containing 16U heparin. Before blood contact, specimens were rinsed twice in phosphate-buffered saline (PBS). The specimens were then incubated in 6-well plates in 2 ml blood for 10 min under dynamic conditions on a platform shaker (speed level 4; Titramax 100, Heidolph Instruments, Schwabach, Germany). After incubation, specimens were rinsed in PBS in order to eliminate non-adherent cells and analysed.

CD61 Immunohistochemistry

Formation of platelet aggregates is mediated by cell adhesion molecules like CD61. CD61 (integrin β-3) is a glycoprotein found on both activated and inactive platelets and is involved in cell adhesion, spreading and platelet
aggregation during haemostasis. Integrin is activated via G-protein coupled signal transduction and then binds fibrinogen. Fibrinogen stabilizes the aggregation of activated platelets by fibrinogen bridges. CD61 is a part of the platelet glycoprotein receptor IIb/IIIa (αIIbβ3; CD41/CD61) [20]. CD41/CD61 is known to bind to a variety of proteins including fibrinogen, fibronectin, von Willebrand factor and vitronectin [20]. CD61-positive adherent platelets were stained using CD61-PE antibody (BD Pharmingen, Heidelberg, Germany) fluorescence staining. After incubation in whole blood, nickel titanium specimens were rinsed in PBS twice in order to remove non-adherent cells. The antibody was diluted 1:5 in PBS and added to the nickel titanium specimens. After 15-min incubation in the dark, nickel titanium specimens were rinsed in PBS twice, fixed with 1% paraformaldehyde (Sigma-Aldrich, Taufkirchen, Germany) in PBS and analysed using a fluorescence microscope (Olympus BX40, Olympus; Hamburg, Germany) equipped with a digital camera (Moticam 5, Motic, Wetzlar, Germany).

Scanning Electron Microscopy (SEM)

SEM was performed on a LEO 1530 Gemini (Carl Zeiss AG, Jena, Germany) equipped with an ISIS EDX system (Oxford Instruments, Wiesbaden, Germany). For SEM analyses specimens were incubated in whole blood for 10 min, rinsed in PBS twice, fixed with 3.7% glutaraldehyde (Sigma-Aldrich, Taufkirchen, Germany) in PBS for 15 min, dehydrated by an ascending series of alcohols, dried for 24 h at room temperature and sputtered with gold (Edwards Sputter Coater S150B9, Edwards Limited, Crawley, UK). SEM analyses were performed at the Ruhr-Universität Bochum, Faculty of Mechanical Engineering, Department of Materials.

Semi-quantitative Phase Analyses

The positive area of platelet staining (CD 61 +ve stained cells) was analysed using ImageJ software (National Institutes of Health, Bethesda, MD) within defined regions of interest, 4 per nickel titanium plate, which were maintained for all samples (0.06 mm² each, total are 0.24 mm²). The results were reported as percentage of positively stained area, which was calculated by dividing the absolute positive area by the predefined area of the region of interest.

Statistical Analysis

Data were analysed by the Kruskal–Wallis test. If a significant difference was found, treated groups were compared with the control group by using Dunn’s post-test. GraphPad Prism software (version 3.03; GraphPad Software Inc., La Jolla, CA) was used for the analysis. P values of less than 0.05 were considered statistically significant. We started by testing the HPC-I and HPC-II coatings at the same time and in comparison with uncoated specimens. After 5 experiments of the HPC-I and HPC-II coatings, the experiments with HPC-I were abandoned due to futility. Further, ten experiments were conducted with the HPC-II coating in comparison with uncoated specimens (Table 1).

Results

The HPC-I and the HPC-II Coatings Increase Hydrophilicity

Small droplets of water were applied onto the surface of the uncoated specimens. The droplets maintain a spherical shape on the surface of the nickel titanium plates (Fig. 1A, 20 µL) as well as on the braided flow diverter stents (Fig. 1B, 2 µL). Coating of the specimens results in an increased hydrophilicity. Application of the same amount of water on a coated specimen leads now to a breakdown in the surface tension of the water droplet and dispersion of the water over the surface of both the nickel titanium plate (Fig. 1C) and the flow diverter (Fig. 1D). The changes in the hydrophilic properties, which indicate the successful coating of the samples, were used to monitor the coating efficiency.

The HPC-II Coating Significantly Reduces Adherence of CD61-Positive Platelets on Nickel Titanium Plates

The anti-thrombogenic properties of the HPC-I, HPC-II and uncoated nickel titanium plates were tested by incubating with whole blood, under dynamic conditions on a platform shaker, for 10 min. The blood, taken from healthy volunteers (n = 8), was non-medicated. Adherent platelets were visualized via a fluorescent CD61 antibody using a fluorescence microscope. Representative images are shown in Fig. 2. On the HPC-II-coated specimens very few CD61-positive cells were detected (Fig. 2). This effect was true for all blood donors. Quantitative Phase Analyses revealed a highly significant difference in the surface area covered in thrombocytes between the bare (48.61 ± 7.3%) and HPC-I (40.19 ± 8.9%) compared to the HPC-II-coated (1.12 ± 0.4%) nickel titanium plates.

| Table 1 | The total number of experiments performed for each coating |
|---------|----------------------------------------------------------|
| HPC-I   | 5                                                       |
| HPC-II  | 15                                                      |
| Bare    | 15                                                      |

n = 5
The HPC-II Coating Significantly Reduces Adherence of CD61-Positive Platelets When Applied to Two FDS of Different Design

The HPC-II coating was applied to two different flow diverters (p48 and p64, phenox, Germany). Both flow diverter stents were incubated in whole blood for 10 min under dynamic conditions on a platform shaker (speed level 4; Titramax 100, Heidolph Instruments, Schwabach, Germany).

The uncoated (bare) specimens showed extensive coverage of the wires with adherent CD61 positive platelets and clumping of thrombocytes at the crossing points of the braided wires. The HPC-II-coated specimens exhibited a very low level of CD61 fluorescence (Fig. 3) with only sparse immunofluorescence and no clumping of thrombocytes. Due to their highly complex geometry, analysis of platelet adhesion and cell counts on flow diverters is difficult, and therefore, these analyses were restricted to the nickel titanium plates.

Minimal Platelet Aggregation is Seen on HPC-II-Coated FDS on Electron Microscopic Examination

In order to visualize the morphology of both the cells and the flow diverter surface, scanning electron microscope (SEM) pictures of coated and uncoated p48 flow diverter stents after incubation in whole blood for 10 min under dynamic conditions were taken. The micrographs are shown in Fig. 4. The uncoated stent shows a prominent layer of adherent cells (Fig. 4, bare). Cells adhere on the stent surface and on each other, forming small agglomerates (the preliminary stage of a blood clot) on and between the single wires of the stent. At higher magnification platelets on the uncoated flow diverter stent are diffusely spread over the wires of the FDS and they form a dense layer of cells. On the HPC-II-coated FDS, there are sparse cells adherent to the wires. Individual thrombocytes tended to adhere in the vicinity of defects on the wire surface (Fig. 4, HPC-II). Cell agglomerates were not detected.
As these flow diverters are designed for different sized vessels, it is beneficial that the coating can be applied to both designs and raises hope that the coating could be applied to other intracranial stents other than flow diverters.

The development of clots on the surface of stents implanted in arterial structures could have significant clinical consequences, e.g. acute thromboembolic stroke. In order to prevent this from occurring, the standard approach to date has been to use anti-platelet agents that inhibit the formation of organized clots on the surface of the stents. The need for a stringent dual anti-platelet treatment (DAPT), typically involving aspirin and clopidogrel, prior to the implantation of stents has been advocated to reduce thromboembolic complications [25–27], and it is generally accepted that effective inhibition of platelet function can be achieved through DAPT [16, 28]. However, even with an optimized dosage of the anti-aggregant medication, the risk of thrombosis remains between 0.5 and 15% after stenting of the supra-aortic branches or vessels of the cerebrovascular circulation, being about seven times higher in intracranial vessels than in the coronary circulation [29, 30].

Despite numerous scientific efforts, especially in cardiology, it has not yet been possible to develop optimized anti-thrombogenic vascular implants. Regardless of a series of promising results in vitro [31–33], these coatings have not yet been successfully transferred to an endovascular device. Although the coating materials used to date for the coating of stents and flow diverters have bio- and haemo-compatible properties [32, 34], DAPT is still necessary. Approaches from other medical fields (e.g. the ProBIO® coating of cardiovascular stents from Biotronik) or coatings used on catheters, contact lenses or in the field of molecular diagnostics in microarrays could offer new approaches for solving this problem. A transfer of such a coating to the highly complex geometry of flow diverters has not yet been shown successfully. Other anti-thrombogenic stent coatings (e.g. of the COBRA coronary stent, coated with polyzene-F) have anti-thrombogenic properties, but only shorten the period during which DAPT is required [35]. This may reduce the haemorrhagic risk of “responders”, but the management of “non-responders” and patients with acute haemorrhagic stroke is not facilitated by these coating concepts.

The development of devices that would minimize, or completely negate, the need for anti-platelet medication would represent a major leap forward. These devices would potentially limit the risks of both thrombogenic and haemorrhagic complications. Currently, the Pipeline Shield (Medtronic) is undergoing early-stage trials. This device has shown promising early results with 1.72 times fewer clots seen compared to the original pipeline device in one animal study [36] and similar results in an ex vivo model [37]. Several case reports have been published on the use of this device in patients with both ruptured and unruptured aneurysms [38–40]. In two of these cases there were no

**Discussion**

Thrombosis on the surface of stents is complex, but protein adsorption seems to be the first step in the material–blood interaction, activating the intrinsic and extrinsic pathways of coagulation [21, 22]. The second step is platelet “rolling” and finally adhesion to the surface, or more accurately, to the adherent proteins on the surface. Eventually this process, together with different levels of trauma to the vessel wall related to the implantation of stents, may lead to the formation of platelet aggregates that progressively evolve into organized clots, and the activation of a local inflammatory response [21, 23, 24]. The results of our study showed a significant decrease in the number of CD61+ve cells adherent to the HPC-II-coated nickel titanium plates as well as minimal thrombocytes adherent to the actual FDS with the HPC-II coating under electron microscopy. Given the complex geometry of flow diverters and the numerous contact points between the braided wires of the flow diverter, it is essential that any coating can be robustly applied to these wires. The ability to apply the HPC-II surface coating to nickel titanium wires, which can then be used to fabricate flow diverters, represents a significant step forward in the generation of devices that may not require dual anti-platelet use in clinical practice as well as minimizing the formation of clots on the surface of these devices. Furthermore, these results have shown that the coating is effective on two different flow diverter designs as both the p48, a flow diverter with 48 braided wires, and the p64, with 64 braided wires, were successfully coated. As these flow diverters are designed for different sized vessels, it is beneficial that the coating can be applied to

![Fig. 4 SEM micrographs of uncoated (bare) and HPC-II-coated p48 flow diverter stents. The specimens were incubated in whole blood for 10 min under dynamic conditions. Stents and adherent cells were fixed and sputtered with gold. The rectangle in the upper row indicates the area shown in a higher magnification below](image-url)
thromboembolic complications; however, in the case of Hanel et al. [39] the stent construct was thrombosed at the 10-day follow-up angiography and anti-platelet testing done at this time revealed an inadequate response to the maintenance dose of aspirin (81 mg). More recently, the early results from a prospective study using the Pipeline Flex with Shield technology have been published [41]. Fifty patients were enrolled in this prospective, single-arm, multicentre study of unruptured aneurysms. Anti-platelet testing was not mandatory. The vast majority of patients, 88% of those enrolled (44/50), received DAPT prior to treatment, and post-operatively all patients were on DAPT. In the 30-day post-operative period, there were 5 non-serious adverse events and 3 serious adverse events (SAE) as adjudicated by the clinical events committee (CEC), none of which were related to in-stent stenosis or acute intracranial haemorrhage. Unfortunately, it is still to be determined whether the Pipeline Shield can be used with mono-anti-aggregation.

The results of our study suggest the HPC-II coating is a promising coating that can minimize the thrombogenicity of nickel titanium. The HPC-II coating can be applied to nickel titanium wires which are used in the construction of flow diverter stents. The HPC-II coating has become “pHPC” as a part of the phenox brand name, and early clinical testing of flow diveters with this surface modification has begun with promising early results.

**Conclusion**

This study demonstrates a significant decrease in the number of adherent CD61+ve platelets on nickel titanium surfaces coated with the HPC-II coating compared to uncoated surfaces. The coating can be successfully applied to the wires of flow diveters where minimal adherent platelets were seen under electron microscopy. The results of this study are promising with regard to the development of new anti-thrombogenic endovascular devices. The HPC-I and HPC-II were working titles. HPC-II has become “pHPC” as a part of the phenox brand name.

**Compliance with Ethical Standards**

**Conflict of interest** TLH is employed in the R&D department of phenox. PB is a consultant and proctor for phenox and Neurvana Medical. MP, AB declared no conflict of interests. RMM is a consultant and proctor for phenox. HH is a co-founder and shareholder of phenox. HM is a co-founder, shareholder and CEO of phenox.

**Ethical Statement** All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

1. Kadirvel R, Ding Y-H, Dai D, Rezek I, Lewis DA, Kallmes DF. Cellular mechanisms of aneurysm occlusion after treatment with a flow diverter. Radiology. 2014;270:394–9.
2. Becske T, Kallmes DF, Saatci I, McDougall CG, Szikora I, Lanzino G, et al. Pipeline for uncoilable or failed aneurysms: results from a multicenter clinical trial. Radiology. 2013;267:858–68.
3. Nelson PK, Lylyk P, Szikora I, Wetzel SG, Wanke I, Fiorella D. The pipeline embolization device for the intracranial treatment of aneurysms trial. AJNR Am J Neuroradiol. 2011;32:34–40.
4. Briganti F, Leone G, Marseglia M, Marinello G, Caranci F, Brunetti A, et al. Endovascular treatment of cerebral aneurysms using flow-diverter devices: a systematic review. Neuroradiol J. 2015;28:365–75.
5. Mpotsaris A, Skalej M, Beuing O, Eckert B, Behme D, Weber W. Long-term occlusion results with SILK flow diversion in 28 aneurysms: do recanalizations occur during follow-up? Interv Neuroradiol J Perioperative Neuroradiol Surg Proced Relat Neurosci. 2015;21:300–10.
6. Strauss I, Maimon S. Silk flow diverter in the treatment of complex intracranial aneurysms: a single-center experience with 60 patients. Acta Neurochir (Wien). 2016;158:247–54.
7. Kocer N, Islak C, Kizilkilic O, Kocak B, Saglam M, Tureci E. Flow Re-direction Endoluminal Device in treatment of cerebral aneurysms: initial experience with short-term follow-up results. J Neurosurg. 2014;120:1158–71.
8. Saatci I, Yavuz K, Ozor C, Geyik S, Cekirge HS. Treatment of intracranial aneurysms using the pipeline flow-diverter embolization device: a single-center experience with long-term follow-up results. AJNR Am J Neuroradiol. 2012;33:1436–46.
9. Fischer S, Vajda Z, Aguilar Perez M, Schmid E, Hopf N, Bänzer H, et al. Pipeline embolization device (PED) for neurovascular reconstruction: initial experience in the treatment of 101 intracranial aneurysms and dissections. Neuroradiology. 2012;54:369–82.
10. Bhogal P, Pérez MA, Ganslandt O, Bänzer H, Henkes H, Fischer S. Treatment of posterior circulation non-saccular aneurysms with flow diverters: a single-center experience and review of 56 patients. J Neurointerventional Surg. 2016;9:471–81.
11. Bhogal P, Martinez Moreno R, Ganslandt O, Bänzer H, Henkes H, Pérez MA. Use of flow diverters in the treatment of unruptured saccular aneurysms of the anterior cerebral artery. J Neurointerventional Surg. 2017;9:283–9.
12. Bhogal P, Hellstern V, Bänzer H, Ganslandt O, Henkes H, Aguilar Pérez M. The use of flow diverting stents to treat paraophthalmic aneurysms. Front Neurol. 2017;8:381.
13. Bhogal P, Ganslandt O, Bänzer H, Henkes H, Pérez MA. The fate of side branches covered by flow diverters-results from 140 patients. World Neurosurg. 2017;103:789–98.
14. Dotter CT. Transluminally-placed coilspine endarterial tube grafts. Long-term patenty in canine popliteal artery. Invest Radiol. 1969;4:329–32.
15. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al. A clinical trial comparing three antithrombotic-drug
regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339:1665–71.
16. Kastrati A, Schühlen H, Hausleiter J, Walter H, Zitzmann-Roth E, Hadamitzky M, et al. Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy: six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial. Circulation. 1997;96:462–7.
17. Chen C, Lumsden AB, Ofenloch JC, Noe B, Campbell EJ, Stratford PW, et al. Phosphorylcholine coating of ePTFE grafts reduces neointimal hyperplasia in canine model. Ann Vasc Surg. 1997;11:74–9.
18. Chen C, Ofenloch JC, Yianni YP, Hanson SR, Lumsden AB. Phosphorylcholine coating of ePTFE reduces platelet deposition and neointimal hyperplasia in arteriovenous grafts. J Surg Res. 1998;77:119–25.
19. Campbell EJ, O’Byrne V, Stratford PW, Quirk I, Vick TA, Wiles MC, et al. Biocompatible surfaces using methacryloylphosphorylcholine laurylmethylacrylate copolymer. ASAIO J Am Soc Artif Intern Organs. 1992;1994(40):M853–7.
20. Shattil SJ, Kashiwagi H, Pampori N. Integrin signaling: the platelet paradigm. Blood. 1998;91:2645–57.
21. Gorbet MB, Sefton MV. Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. Biomaterials. 2004;25:5681–703.
22. Mikhailovska LI, Santin M, Denyer SP, Lloyd AW, Teer DG, Field S, et al. Fibrinogen adsorption and platelet adhesion to metal and carbon coatings. Thromb Haemost. 2004;92:1032–9.
23. Versteeg HH, Heemskerk JWM, Levi M, Reitsma PH. New fundamentals in hemostasis. Physiol Rev. 2013;93:327–58.
24. Reining AJ. Function of von Willebrand factor in hemostasis and thrombosis. Haemoph Off J World Fed Hemoph. 2008;14(Suppl 5):11–26.
25. Delgado Almandoz JE, Crandall BM, Scholz JM, Fease JL, Anderson RE, Kadkhodayan Y, et al. Last-recorded P2Y12 reaction units value is strongly associated with thromboembolic and hemorrhagic complications occurring up to 6 months after treatment in patients with cerebral aneurysms treated with the pipeline embolization device. AJNR Am J Neuroradiol. 2014;35:128–35.
26. Delgado Almandoz JE, Crandall BM, Scholz JM, Fease JL, Anderson RE, Kadkhodayan Y, et al. Pre-procedure P2Y12 reaction units value predicts perioperative thromboembolic and hemorrhagic complications in patients with cerebral aneurysms treated with the Pipeline Embolization Device. J Neurointerventional Surg. 2013;5(Suppl 3):iii3–10.
27. Daou B, Starke RM, Chalouhi N, Barros G, Tjoumakaris S, Rosenwasser RH, et al. P2Y12 reaction units: effect on hemorrhagic and thromboembolic complications in patients with cerebral aneurysms treated with the pipeline embolization device. Neurosurgery. 2016;78:27–33.
28. Honda Y, Fitzgerald PJ. Stent thrombosis: an issue revisited in a changing world. Circulation. 2003;108:2–5.
29. Moulakakis KG, Mylonas SN, Lazaris A, Tsivgoulis G, Kakisis J, Sfyroeras GS, et al. Acute carotid stent thrombosis: a comprehensive review. Vasc Endovascular Surg. 2016;50:511–21.
30. Riedel CH, Tietke M, Aflke K, Stengele R, Jansen O. Subacute stent thrombosis in intracranial stenting. Stroke. 2009;40:1310–4.
31. Lopez-Donaire ML, Santerre JP. Surface modifying oligomers used to functionalize polymeric surfaces: consideration of blood contact applications. J Appl Polym Sci. 2014;131:40328.
32. Muramatsu T, Onuma Y, Zhang Y-J, Bourantas CV, Kharlamov A, Diletti R, et al. Progress in treatment by percutaneous coronary intervention: the stent of the future. Rev Espanola Cardiol Engl Ed. 2013;66:483–96.
33. Kaplan O, Hierlemann T, Krajewski S, Kurz J, Nevoralova M, Houska M, et al. Low-thrombogenic fibrin-heparin coating promotes in vitro endothelialization. J Biomed Mater Res A. 2017;105:2995–3005.
34. Shuvalova YA, Shirokov RA, Kaminnaya VI, Samko AN, Kaminnyi AL. Two-year follow-up of percutaneous coronary intervention using EucaTax or Cypher. Cardiovasc Revascularization Med Mol Interv. 2013;14:284–8.
35. Cutlip DE, Garratt KN, Novack V, Barakat M, Meraj P, Maillard L, et al. 9-month clinical and angiographic outcomes of the COBRA polyzene-F nanocoated coronary stent system. JACC Cardiovasc Interv. 2017;10:160–7.
36. Marosof M, Clarencon F, Langan ET, King RM, Brooks OW, Tamura T, et al. Acute thrombus formation on phosphorylcholine surface modified flow diverters. J Neurointerventional Surg. 2017;10:406–11.
37. Hagen MW, Girdhar G, Wainwright J, Hinds MT. Thrombogenicity of flow diverters in an ex vivo shunt model: effect of phosphorylcholine surface modification. J Neurointerventional Surg. 2017;9:1006–11.
38. Chiu AHY, Ramesh R, Wenderoth J, Davies M, Cheung A. Use of aspirin as sole oral antiplatelet therapy in acute flow diversion for ruptured dissecting aneurysms. J Neurointerventional Surg. 2017:9:e18.
39. Hanel RA, Aguilar-Salinas P, Brasiliense LB, Sauvageau E. First US experience with pipeline flex with shield technology using aspirin as antiplatelet monotherapy. BMJ Case Rep. 2017. https://doi.org/10.1136/bcr-2017-219406.
40. Orlov K, Kisiltis D, Strelnikov N, Berestov V, Gorbatykh A, Shayakhmetov T, et al. Experience using pipeline embolization device with Shield Technology in a patient lacking a full postoperative dual antiplatelet therapy regimen. Interv Neuroradiol J Perioperative Neuroradiol Surg Proced Relat Neurosci. 2018. https://doi.org/10.1177/1591019917753824.
41. Martinez-Galdamez M, Lamin SM, Lagios KG, Liebig T, Ciceri EF, Chapat R, et al. Periprocedural outcomes and early safety with the use of the Pipeline Flex Embolization Device with Shield Technology for unruptured intracranial aneurysms: preliminary results from a prospective clinical study. J Neurointerventional Surg. 2017;9:772–6.